Preview

Артериальная гипертензия

Расширенный поиск

Особенности лечения сахарного диабета 2 типа у пациентов с коморбидной патологией

https://doi.org/10.18705/1607-419X-2009-15-1-31-41

Полный текст:

Аннотация

У пациентов с сахарным диабетом типа 2 распространенность заболеваний сердечно-сосудистой системы крайне высока, а риск развития фатальных сердечно-сосудистых событий у них в 2-6 раз выше, чем у пациентов без сахарного диабета. У пациентов с сахарным диабетом типа 2 высока частота макрососудистых осложнений, таких как инсульт, атеросклероз периферических артерий, и сердечно-сосудистые осложнения являются основной причиной смерти у этой группы людей. В данном обзоре рассматриваются вопросы эффективности и безопасности различных сахароснижающих препаратов у пациентов с сахарным диабетом типа 2 и сопутствующей патологией. Обсуждается проблема лечения лиц пожилого возраста с сахарным диабетом типа 2 и сопутствующими заболеваниями, также в статье представлен предлагаемый алгоритм ведения таких пациентов.

Об авторах

Е. В. Шляхто
ФГУ «Федеральный Центр сердца, крови и эндокринологии им. В.А. Алмазова»
Россия


Е. Н. Гринева
ФГУ «Федеральный Центр сердца, крови и эндокринологии им. В.А. Алмазова»
Россия


А. Ю. Бабенко
ФГУ «Федеральный Центр сердца, крови и эндокринологии им. В.А. Алмазова»
Россия


А. В. Дронова
ФГУ «Федеральный Центр сердца, крови и эндокринологии им. В.А. Алмазова»
Россия


Список литературы

1. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281-303.

2.

3. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulindependent diabetes mellitus. N Eng J Med. 1999;329:977-986.

4.

5. Eschwege E. The dysmetabolic syndrome, insulin resistance and increased cardiovascular morbidity and mortality in type 2 diabetes: etiological factors in the development of CV complications. Diabetes Metab. 2003;29:6S19-6S27.

6.

7. Аметов А.С. Инсулиносекреция и инсулинорезистентность: две стороны одной медали. Проблемы эндокринологии. 2002;48(3):31-36.

8.

9. Bloomgarden ZT. Developments in diabetes and insulin resistance. Diabetes Care. 2006;29:161-7.

10.

11. McCance DR, Hanson RL, Pettitt DJ, Bennett PH, Hadden DR, Knowler WC. Diagnosing diabetes mellitus: do we need new criteria? Diabetologia. 1997;40:247-55.

12.

13. Andersson DKG, Lundblad E, Svardsudd K. A model for early diagnosis of type 2 diabetes mellitus in primary health care. Diabet Med. 1993;10:167-73.

14.

15. Odegard PS, Setter SM, Neumiller JJ. Considerations for the Pharmacological Treatment of Diabetes in Older Adults. Diabetes Spectrum. 2007;20:239-47

16.

17. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2006;29:1963-72.

18.

19. Abbasi F, Chu JW, McLaughlin T, Lamendola C, Leary ET, Reaven GM. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism. 2004;53(2):159-164.

20.

21. Standards of Medical Care in Diabetes-2007. Position Statement. Diabetes Care. 2007;30:S4-S41.

22.

23. Cusi K, De Fronzo RA. Metformin: a review of its metabolic effect. Diabetes Rev. 1998;6:89-131.

24.

25. Bailey C, Campbell W. Metformin - The Gold Standrd. A Scientific Handbook; 2007

26.

27. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-13.

28.

29. Sakharova OV, Inzucchi SE. Treatment of diabetes in the elderly. Addressing its complexities in this high-risk group.: Postgrad Med. 2005 Nov;118(5):19-26, 29.

30.

31. Бабичев В.Н., Савельева М.П., Балаболкин М.И. Характеристика рецепторов b-клеток поджелудочной железы, связывающих сульфонилмочевинные препараты. Проблемы Эндокринол. 1994;6:47-50.

32.

33. Александров А.А., Бондаренко И.З., Кухаренко С.С. и др. Сахароснижающие сульфаниламиды и «ишемический порог» сердца у больных сахарным диабетом типа 2 с коронарной болезнью сердца. Сахарный диабет. 2002;17(4):18-22.

34.

35. Muller G. The molecular mechanism of insulin-mimetic/sensitizing activity of antidiabetic sulfonylurea drug amaryl. Mol Med. 2000;6:907-33.

36.

37. Peterson MR, Bacon T. A comparison of select cardiovascular outcomes by anti-diabetic prescription drug classes used to treat type 2 diabetes among military health system beneficiaries, fiscal year 2003-2006. Joint meeting of the Endocrinologic and metabolic drugs advisory committee and the Drug safety and risk management advisory committee; 2007

38.

39. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc. 1996;44:751-55.

40.

41. Brodows RG. Benefits and risks with glyburide and glipizide in elderly NIDDM patients. Diabetes Care. 1992;15:75-80.

42.

43. U.K. Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352:837-53.

44.

45. Omnicare, Inc.: Geriatric Pharmaceutical Care Guidelines: Diabetes Mellitus. 2007 ed. Covington, Ky., Omnicare, Inc.; 2007:231-51.

46.

47. Del Prato S, Heine RJ, Keilson L, Guitard C, Shen SG, Emmons RP. Treatment of patients over 64 years of age with type 2 diabetes. Diabetes Care. 2003;26:2075-80

48.

49. Choudhury S, Hirschberg Y, Filipek R, Lasseter K, McLeod JF: Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis. J Clin Pharmcol 2000;40:634-40.

50.

51. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus. Lancet. 2002;359:2072-77.

52.

53. Hannele Yki-Järvinen. Thiazolidinedinones. N Engl J Med. 2004;351:1106-18.

54.

55. Durbin RJ. Thiazolidinedinone therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab. 2004;6:280-5.

56.

57. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003;108:2941-48

58.

59. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-71.

60.

61. Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care. 2002;25:708-11.

62.

63. Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, et al. A Diabetes Outcome Progression Trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care. 2002;25:1737-43.

64.

65. Nielsen LL. Incretin mimetics and DPP-IV ingibitors for the treatment of type 2 diabetes. Drug Discov Today. 2005;10:703-10.

66.

67. Byetta prescribing information. San Diego, Calif. Amylin Pharmaceuticals, Inc.; 2005.

68.

69. Linnebjerg H, Kothare PA, Park S, Mace K, Reddy S, Mitchell M, et al. Effect of renal impairment on the pharmacokinetics of exenatide [article online]. J Clin Pharmacol. 2007.

70.

71. Deacon CF. Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes. Expert Opin Invest Drugs. 2007;16:533-45

72.

73. Herman GA, Bergman A, Yi B, Kipnes M. The Sitagliptin Study 012 Group.Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin. 2006 Oct;22(10):1939-47

74.

75. Kleppinger EL, Vivian EM. Pramlintide for the treatment of diabetes mellitus. Ann Pharmacother 2003;37:1082-9.

76.

77. Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes. Diabetes Care 2003;26:784-90.

78.

79. Janka HU, Plewe G, Busch K. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. J Am Geriatr Soc 2007;55:182-8.

80.

81. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care. 2000;23:1130-6.

82.

83. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-6

84.

85. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357:1716-30.

86.

87. Zarowitz BJ, Tangalos EG, Hollenack K, O'Shea T. The application of evidence-based principles of care in older persons (issue 3): management of diabetes mellitus. J Am Med Dir Assoc 2006;7:234-40.

88.

89. Esposito K, Ciotola M, Maiorino MI, Gualdiero R, Schisano B, Ceriello A, et al. Addition of Neutral Protamine Lispro Insulin or Insulin Glargine to Oral Type 2 Diabetes Regimens for Patients with Suboptimal Glycemic Control: A Randomized Trial. Ann Intern Med. 2008;149:531-9.

90.

91. Dagdelen S, Ilag LL, Martin S, Jacober SJ, Holman RR, Farmer AJ, et al. Addition of insulin to oral therapy in type 2 diabetes.. NEJM. 2008;358:1197-8.

92.

93. Riddle MC. Starting and Advancing Insulin for Type 2 Diabetes: Algorithms and Individualized Methods Are Both Necessary. J Clin Endocrinol Metab. 2008;93:372-4.

94.

95. Porcellati F, Rossetti P, Ricci Busciantella N, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes mellitus: a double-blind, randomized, cross-over study. Diabetes Care (in press).

96.

97. Pfizer, Inc.: Exubera product information; 2007.

98.

99. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical Management of Hyperglicemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. Diabetes Care. 2008;31(1):173-5.

100.


Для цитирования:


Шляхто Е.В., Гринева Е.Н., Бабенко А.Ю., Дронова А.В. Особенности лечения сахарного диабета 2 типа у пациентов с коморбидной патологией. Артериальная гипертензия. 2009;15(1):31-41. https://doi.org/10.18705/1607-419X-2009-15-1-31-41

For citation:


Shlyakhto E.V., Grineva E.N., Babenko A.Y., Dronova A.V. Features of treatment of type 2 diabetes mellitus in patients with concomitant pathology. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2009;15(1):31-41. (In Russ.) https://doi.org/10.18705/1607-419X-2009-15-1-31-41

Просмотров: 96


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)